All In Biotech

Drug Trial Radar · NCT05927571

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Patients With Relapsed or Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Aug 10, 2023

Primary completion

Jul 31, 2027

Study completion Jul 31, 2027

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jul 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate safety and tolerability of the combination of cevostamab plus elranatamab and also determine the recommended Phase II regimen (RP2R) for the study treatment. The study consists of a safety lead-in stage, and an expansion stage.

Conditions

  • Relapsed or Refractory Multiple Myeloma

Interventions

  • CevostamabDrug

    Cevostamab solution for infusion will be administered as IV as specified in each treatment arm.

  • ElranatamabDrug

    Elranatamab solution for injection will be administered SC as specified in each treatment arm.

  • TocilizumabDrug

    Tocilizumab will be used as rescue medication for participants who experience a cytokine release syndrome (CRS) event.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs)Time frame: From signing of informed consent up to end of study (EOS) (approximately 36 months)
  2. Recommended Phase II Regimen (RP2R)Time frame: Up to approximately 36 months

Locations

14 sites in 3 countries. Site status is shown where the registry gives one.

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia · Recruiting

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia · Recruiting

  • Royal Adelaide Hospital;Haematology Clinical Trials Unit

    Adelaide, South Australia, Australia · Recruiting

  • St. Vincent's Hospital Melbourne

    Melbourne, Victoria, Australia · Recruiting

  • The Alfred Hospital

    Prahan, Victoria, Australia · Recruiting

  • Rambam Health Care Campus

    Haifa, Israel · Recruiting

  • Hadassah University Hospital - Ein Kerem

    Jerusalem, Israel · Recruiting

  • Tel Aviv Sourasky Medical Center PPDS

    Tel Aviv, Israel · Recruiting

  • The Chaim Sheba Medical Center - PPDS

    Ramat Gan, Central District, Israel · Recruiting

  • The Catholic University of Korea - Seoul St. Mary's Hospital (Kangnam St. Mary's Hospital)

    Seocho, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea · Recruiting

  • Asan Medical Center.

    Seoul, South Korea · Recruiting

  • Samsung Medical Center - PPDS

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.